Marinus Pharmaceuticals (MRNS)
(Real Time Quote from BATS)
$1.49 USD
+0.06 (4.20%)
Updated Jul 22, 2024 03:26 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Marinus Pharmaceuticals (MRNS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.22 | $15.00 | $2.00 | 404.90% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Marinus Pharmaceuticals comes to $7.22. The forecasts range from a low of $2.00 to a high of $15.00. The average price target represents an increase of 404.9% from the last closing price of $1.43.
Analyst Price Targets (9 )
Broker Rating
Marinus Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.55 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.55 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, eight are Strong Buy, representing 72.73% of all recommendations. A month ago, Strong Buy represented 72.73%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/MRNS.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.55 | 1.55 | 1.55 | 1.55 | 1.55 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
6/18/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
6/18/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
4/16/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Hold |
4/15/2024 | Not Identified | Not Identified | Moderate Buy | Hold |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
3/26/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
3/7/2024 | Not Identified | Not Identified | Hold | Hold |
3/6/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
3/1/2024 | LadenburgThalmann | Michael Higgins | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.55 |
ABR (Last week) | 1.55 |
# of Recs in ABR | 11 |
Average Target Price | $7.22 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 146 of 252 |
Current Quarter EPS Est: | -0.59 |